 Pharmaceutical preparation |
| We claim: 1. Controlled release preparation comprising a plurality of beads having a soluble ... |
|
| Mold apparatus having an outwardly angled seal for encapsulating a glass sheet |
| The present invention concerns an improved mold apparatus and method for at least partially ... |
|
| 4,5,6,7-Tetrahydro-thieno[3,2-c]-pyridine derivatives and process for their preparation |
| Having now described our invention what we claim as new and desire to secure by Letters Patent is: 1... |
|
| Mercaptoacyldihydropyrazole carboxylic acid derivatives |
| OF THE INVENTION The compounds of formula I are useful as hypotensive agents. They inhibit the ... |
|
| 4-(Substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
| About 70% of all renal calculi contain oxalate as the main component of the matrix. In the ... |
|
| Method for producing 1-nitroanthraquinone |
| What is claimed is: 1. A method for producing 1-nitroanthraquinone by nitration of anthraquinone, ... |
|
| N-pyrazinecarbonyl-N'-acylguanidines |
| What is claimed is: 1. A compound of the formula: ##STR3## wherein R.sup.1 is hydrogen or lower ... |
|
| Novel analogs of prostaglandins with 4-oxo-thiazolidinyl nucleus and method of preparation thereof |
| What is claimed is: 1. The compound of the formula ##STR41## wherein R is carboxy, a carboxy salt, ... |
|
|
Substituted derivatives of 2-azabicyclo-[3.3.0]octanes
| Details |
Inventors: Henning, Rainer; Urbach, Hansjorg; Geiger, Rolf; Teetz, Volker; Scholkens, Bernward;
Assignee: Hoechst Aktiengesellschaft (Frankfurt am Main, DE)
Primary Examiner: Raymond; Richard L.
Assistant Examiner: Turnipseed; James H.
Attorney, Agent or Firm: Curtis, Morris & Safford
Compounds of the formula I ##STR1## in which n denotes 0-3, R.sup.1 and R.sup.1' are the same or different and denote hydrogen, alkyl or alkenyl, phenyl or benzyl, each substituted as desired; R.sup.2 denotes hydrogen, alkyl or alkenyl; R.sup.3 denotes hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl or aminoalkyl, alkanoylaminoalkyl, guanidinoalkyl, imidazolylalkyl, indolylalkyl, mercaptoalkyl or alkylthioalkyl, phenylalkyl, hydroxphenylalkyl, phenoxyalkyl or phenylthioalkyl, or R.sup.2 and R.sup.3, together with the C and N atoms carrying them, denote a saturated or unsaturated 4- to 8-membered monocyclic or 8- to 10-membered bicyclic isocycle or heterocycle, optionally monosubstituted or disubstituted by hydroxyl, alkoxy having 1 to 3 C atoms or alkyl, R.sup.4 denotes hydrogen, alkyl, alkenyl, alkadienyl, alkinyl, alkeninyl or alkadiinyl, cycloalkyl, phenyl, benzyl, phenethyl or phenylpropyl, each of which can be optionally monosubstituted or disubstituted; R.sup.5 denotes hydrogen or alkyl, hydroxyl or alkoxy and R.sup.6 denotes hydrogen, optionally substituted alkyl, cycloalkyl, alkenyl, optionally monosubstituted or disubstituted phenyl or naphthyl, their salts, a process for their preparation and their use as medicaments. |
|
DETAILED DESCRIPTION We claim: 1.
A compound of the formula I ##STR140## in which n is a whole number between 0 and 3 inclusive; R.
sup.
1 and R.
sup.
1', being the same or different, are hydrogen; alkyl or alkenyl having 1-8 C atoms; phenyl or benzyl, each unsubstituted or monosubstituted by methyl, halogen, methoxy or nitro; R.
sup.
2 and R.
sup.
3 together with the C and N atoms carrying them form a 2-azabicyclo[3.
3.
0]octane ring system, which is unsubstituted, monosubstituted or distubstituted by hydroxyl, alkoxy having 1-3 C atoms, alkyl having 1-3 C atoms or phenyl; R.
sup.
4 is hydrogen; alkyl, alkenyl, alkadienyl, alkynyl, alkeninyl or alkadiynyl having 1-8 C atoms; cycloalkyl having 3-6 C atoms; phenyl, benzyl, phenethyl or phenylpropyl, each of which is unsubstituted, monosubstituted or disubstituted by halogen, hydroxyl, acetoxy, carboxy, carboxamido, sulfonamido, nitro, methyl ethyl, methoxy, ethoxy or methylenedioxy; R.
sup.
5 is hydrogen; alkyl having 1-5 C atoms; hydroxyl or alkoxy having 1-3 C atoms; R.
sup.
6 is hydrogen; alkyl having 1-12 C atoms; cycloalkyl having 3-12 C atoms; alkenyl having 2-12 C atoms; phenyl or naphthyl, each of which is unsubstituted, monosubstituted or disubstituted by halogen, hydroxyl, acetoxy, carboxy, carboxamido, sulfonamido, nitro, methyl, ethyl, methoxy, ethoxy or methylenedioxy; alkyl having 1-6 C atoms, which is monosubstituted by halogen, hydroxyl, alkoxy having 1-3 C atoms, phenoxy, amino, dialkylamino having 1-6 C atoms, alkanoylamino having 1-3 C atoms, mercapto, alkylthio having 1-3 C atoms, phenylthio, phenylsulfinyl, phenylsulfonyl, phenyl biphenylyl, or naphthyl, the phenyl or naphthyl each being unsubstituted, monosubstituted or disubstituted by halogen, methyl, ethyl, methoxy, ethoxy, nitro, amino, methylamino, dimethylamino, acetylamino, cyano, methylenedioxy or sulfonamido; heteroaryl selected from the group consisting of pyridyl, thienyl, indolyl, benzothienyl, imidazolyl, pyrazolyl and thiazolyl, said heteroaryl being unsubstituted mono-substituted or disubstituted by halogen, methyl, ethyl, methoxy, ethoxy, nitro, amino, methylamino dimethylamino, acetylamino, cyano, methylenedioxy, sulfonamido or phenyl; or physiologically tolerable salts thereof
|
| Related patents |
|
|
N-(3,3-diphenylpropyl) aminoethyl esters of 1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid, compositions and use
OF THE INVENTION More particularly according to the present invention, it will be appreciated that a variety of syntheses are encompassed within the metes and bounds of ...
|
|
|
Pharmaceutical composition for the treatment of high blood pressure
We claim: 1. A pharmaceutical composition containing a synergistically effective amount of: (a) an angiotensin converting enzyme inhibitor, or its physiologically ...
|
|
|
Method of treating epithelial disorders
We claim: 1. A method of treating subjects suffering from psoriasis which comprises the systemic administration to said subjects of an effective amount of a compound of ...
|
|
|
Process for preparing carboline derivatives
OF THE INVENTION In accordance with the process of this invention, substantially equimolar amounts of the unsubstituted amine starting material, the acetylenic reagent ...
|
|
|
Imidazodiazepine derivatives
What is claimed: 1. A compound of the formula ##STR31## wherein A together with the two carbon atoms denoted as .alpha. and .beta. is selected from the group consisting ...
|
|
|
Process for making epsilon-caprolactam
We claim: 1. A process for manufacturing epsilon-caprolactam comprising passing cyclohexanone oxime over a zeolite having a silica to alumina ratio of at least 12 and a C...
|
|
|
1,4-Substituted piperazinyl derivatives useful as psychostimulants
What is claimed is: 1. A compound of formula I, ##STR17## wherein each of R.sub.1 and R.sub.4, which may be the same or different, is hydrogen, halogen of atomic number ...
|
|
|
Process for the preparation of tablets with retarded liberation of the active agent is predetermined
What we claim is: 1. Process for the preparation of controlled release tablets containing an active agent comprising: (a) granulating the active agent with an organic ...
|
|
|
Method for the preparation of granulates suited for the production of sustained release coated tablets for oral use
What is claimed is: 1. A process for the preparation of tablets slowly releasing an active principle which consists essentially of preparing a mixture containing said ...
|
|
|
Erythromycin microencapsulated granules
OF THE INVENTION The invention relates to pharmaceutically active microencapsulated granules comprising erythromycin and a binder. Such erythromycin granules are ...
|
|
|
Vasodialators 
